CEPI Revenue and Competitors

CEPI - Coalition for Epidemic Preaparedness Innovations - is a new broad international coalition set up to fund development of vaccines against emerging infectious diseases with epidemic potential, where there are few market incentives. The epidemics like Ebola and SARS we have seen over the past years, have demonstrated the need for vaccines. Development of a vaccine takes many years, and it is too late to start when the outbreak has started. By having vaccines on the shelf ready for phase III early in an outbreak, we can demonstrate the vaccine efficacy and stop the outbreak while it is small. CEPI has already launched two calls for proposals; one for development of vaccines against MERS, Lassa and Nipah and one for the development of rapid response vaccine technology to enable development of vaccines against new and unknown diseases. CEPI was launched in January 2017 and now has funding totalling $620 million from soverign investors and philantropic institutions. CEPI's investors are: The Governments of Australia, Belgium, Canada, Japan and Norway, as well as the Wellcome Trust and the Bill&Melinda Gates Foundation. In addition the European Commission will co fund activities with 250 million.